Skip to main content
Adocia logo

Adocia — Investor Relations & Filings

Ticker · ADOC ISIN · FR0011184241 LEI · 969500ZL79KYH9PTYP78 PA Real estate activities
Open in API
Filings indexed 828 across all filing types
Latest filing 2022-10-20 Declaration of Voting R…
Country FR France
Listing PA ADOC

About Adocia

https://www.adocia.com

Adocia is a clinical-stage biotechnology company that specializes in developing innovative treatments for metabolic diseases, with a primary focus on diabetes and obesity. The company's core expertise is the development of novel formulations of approved peptides, proteins, and metabolic hormones, such as insulin, to improve their therapeutic efficacy. Adocia leverages proprietary technology platforms to create a pipeline of specialty products. Its research also extends to novel cell therapy approaches, including an immunoprotective scaffold for cell delivery. The company's business model involves advancing its product candidates to clinical proof-of-concept before licensing them to partners for late-stage development and commercialization.

Recent filings

Filing Released Lang Actions
Franchissement de seuils
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled "Déclaration de franchissement de seuils (article L. 233-7 du code de commerce)" which translates to 'Declaration of crossing thresholds (Article L. 233-7 of the Commercial Code)'. This type of filing in France (indicated by the AMF reference and the commercial code citation) is a mandatory disclosure when a shareholder's stake crosses specific percentage thresholds (e.g., 5%, 10%, 15%, 20%). This specifically relates to changes in significant share ownership. Among the provided codes, 'Major Shareholding Notification' (MRQ) is the closest match for mandatory disclosure of changes in significant share ownership levels crossing thresholds. The document details the new percentage holdings of Bpifrance in ADOCIA.
2022-10-20 French
Informations privilégiées / Autres communiqués
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled "Information relative au nombre d'actions et de droits de vote en date du 30 septembre 2022" and explicitly states it is published in compliance with French commercial code (Code de Commerce) and AMF regulations (Article 223-16). It provides a table detailing the total number of shares and voting rights (BRUT and NET) as of a specific date (September 30, 2022). This type of mandatory periodic disclosure regarding the total share capital and voting rights is a specific regulatory requirement in France, often related to major shareholding notifications or capital structure updates. Since it is a direct announcement of a specific regulatory metric (share capital/voting rights) and not a comprehensive financial report (10-K, IR) or a general regulatory filing fallback (RNS), it fits best under Major Shareholding Notification (MRQ) or potentially a specific capital change announcement. Given the focus is purely on the count of shares and voting rights, which is a key component of major shareholding disclosures, MRQ is the most appropriate fit among the provided options, although it is a very specific type of disclosure not perfectly aligned with the general 'Major Shareholding Notification' definition which usually implies crossing a threshold. However, the content is a direct report of capital structure metrics required by regulators, making it more specific than RNS. It is not a DIV, SHA, or POS as it is reporting the current total, not announcing a transaction or dividend. I will classify it as MRQ as it relates to the composition of ownership/capital structure reporting.
2022-10-13 French
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is explicitly titled '# P R E S S R E L E A S E' and announces the 'Total number of outstanding shares as well as its voting rights as of September 30th, 2022' pursuant to French regulatory articles (L. 233-8 II of the French « Code de Commerce » and article 223-16 of the AMF charter). This type of periodic disclosure regarding share capital structure and voting rights is a standard regulatory announcement. It is not a full Annual Report (10-K), an Earnings Release (ER), or a Dividend Notice (DIV). Since it is a specific regulatory disclosure concerning share capital changes/status, it fits best under the general 'Regulatory Filings' (RNS) category, as there is no specific code for 'Share Capital Status Update' outside of the major forms. Given the context of mandatory disclosure under AMF rules, RNS is the most appropriate general regulatory filing code.
2022-10-13 English
Informations privilégiées / Autres communiqués
Earnings Release Classification · 1% confidence The document is a press release from Adocia announcing "résultats supplémentaires exceptionnels" (exceptional supplementary results) regarding its M1Pram study, specifically presenting *post-hoc* analysis data on weight loss and glycemic control in obese Type 1 diabetes patients. It mentions that these results were presented at the 58th annual EASD congress. This format—a formal announcement of clinical trial results and scientific findings, often released concurrently with or shortly after a scientific conference presentation—is characteristic of an Earnings Release (ER) or a general announcement. Since it is a detailed announcement of specific clinical data and business updates rather than a full, comprehensive financial report (10-K or IR), and it is not merely announcing the publication of a report (RPA), the most fitting category is Earnings Release (ER), as these often include key operational/clinical milestones alongside financial context, or it could be classified as a Regulatory Filing (RNS) if it were less focused on results. Given the focus on presenting new, significant clinical data, ER is a strong fit, although it is not a standard quarterly earnings report. However, since it is a formal announcement of significant operational/clinical progress, and it is not a transcript (CT), presentation (IP), or management discussion (MDA), ER is the closest fit for a major announcement of period-specific results. If the document were purely about the presentation itself, AGM-R might apply, but this is the company's summary of the findings. Given the context of presenting new data, ER is chosen over the general RNS fallback. FY 2022
2022-10-06 French
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is a press release from Adocia announcing 'outstanding additional results' from a Phase 2 study for their drug M1Pram, including specific weight loss data and comparisons to a reference insulin. It details clinical findings, mentions presentation at a scientific meeting (EASD Annual Meeting), and discusses future strategic partnerships. This format—a formal announcement of recent scientific/clinical progress and financial/operational updates—is characteristic of an Earnings Release (ER) or a general press release detailing operational achievements. Since it focuses on announcing key results rather than providing a comprehensive, period-end financial statement (like a 10-K or IR), 'ER' (Earnings Release) is the most appropriate fit, as these releases often contain operational highlights that drive investor interest, even if they aren't strictly quarterly earnings figures. It is not a full transcript (CT), a formal annual report (10-K), or a simple notice of dividend (DIV). Given the content is a detailed announcement of study results, ER is selected over the broader RNS.
2022-10-06 English
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is titled 'Press Release' and announces that the company 'Adocia' will attend several upcoming investor events/meetings in October and November 2022. It details the nature of these meetings ('one-to-one' or 'one-to-few' formats) and what management will discuss (clinical and scientific advances). This content is a direct communication to the investment community about future engagement opportunities, which aligns best with an Investor Presentation (IP) if it were the presentation itself, or more generally, an announcement related to investor relations activities. Since it is an announcement about attending external investor events rather than releasing a formal report (like 10-K, IR, ER) or providing proxy materials, it is a form of investor communication. Given the options, this is a specific announcement targeting investors about future engagement, which is often grouped with Investor Presentations (IP) or general Investor Relations material. However, since it is a press release announcing *attendance* at external events, it functions as a general update to the market about investor outreach. It is not a formal regulatory filing like 10-K, nor is it a transcript (CT) or an earnings release (ER). It is closest to an Investor Presentation (IP) in spirit (investor focus) but is technically an announcement of future meetings. Given the available codes, and recognizing this is a proactive communication to investors about upcoming engagement, 'IP' (Investor Presentation) is the most suitable category for investor-focused material that isn't a formal financial report or a specific transaction notice. If 'RPA' (Report Publication Announcement) were used, it would imply announcing a report, which is not the case here. Therefore, classifying it as Investor Presentation material due to its focus on management meetings and scientific updates seems appropriate for a premium database.
2022-10-03 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.